Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593650 | 0.98 | SLC6A2 (0.51) | SLC6A2SLC6A4CDK4CCND1SLC2A1 | |
| SCHEMBL10774534 | 0.97 | SLC6A2 (0.51) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL22810523 | 0.95 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL29412428 | 0.92 | SLC6A2 (0.59) | SLC6A2SLC6A4CDK4CCND1SLC2A1 | |
| SCHEMBL704340 | 0.92 | SLC6A2 (0.59) | SLC6A2SLC6A4CDK4CCND1SLC2A1 | |
| SCHEMBL23940127 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL2356506 | 0.90 | SLC6A2 (0.46) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL30619477 | 0.89 | SLC6A2 (0.48) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL11168356 | 0.83 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL30641149 | 0.78 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | SLC6A2 3405/4885SLC6A4 4163/4885CDK4 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.